Der Einfluss des Ernährungsverhaltens auf die Rechte künftiger Generationen am Beispiel des Fleischkonsums in Deutschland

Künftige Generationen haben das Recht auf eine Welt, die mindestens den Lebensstandard und Komfort von heute ermöglicht. Schreitet die Erderwärmung allerdings in prognostiziertem Tempo voran, kann dies nicht mehr gewährleistet werden. Einen großen Einfluss auf CO2-Emissionen hat der Verbraucher mit seinem Ernährungsstil. Vor allem der Konsum von Fleisch weist eine schlechte Klimabilanz auf. Indirekte Folgen sind Armut in Entwicklungsländern (Nord-Süd-Konflikt) und die Ausbeutung von Land und weiteren natürlichen Ressourcen künftiger Generationen. Ein bewusster und nachhaltiger Ernährungsstil kann dem entgegen wirken. Aber nicht nur der Konsument allein ist für die Reduzierung von Treibhausgas-Emissionen verantwortlich. Auch Politik und Handel sind gefordert. Denn nur in Gemeinschaft kann der Klimawandel verzögert und eine Generationengerechtigkeit aufrechterhalten werden

A Study of Bus Stop Accessibility: Public Health Students Working in Partnership with the Center for Independent Living

Over 54 million U.S. citizens report living with at least one disability. The Americans with Disabilities Act stipulates legislation that prohibits the discrimination of persons on the basis of disability. Rather than riding the bus in areas that offer a fixed-route bus system, individuals with disabilities often rely on expensive and limited paratransit services, or on family and friends. It has been proposed that with improvements in bus accessibility, riders with disabilities could use the fixed-route system more often and increase their options for independence and community participation. During their 2008 spring semester, participants in the University of Florida College of Public Health and Health Professions’ course, Assessment and Surveillance, partnered with the Center for Independent Living (CIL) of North Central Florida to conduct an accessibility study of the Gainesville, Florida fixed-route bus system. Students focused on factors that make bus stops user-friendly for persons with disabilities. This paper presents the rationale, methods, and findings from this accessibility study and efforts undertaken to forge a mutually beneficial partnership among UF-PHHP students and the CIL

Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study.

Modeling of retrospectively collected multi-center data of a rare disease in pediatrics is challenging because laboratory data can stem from several decades measured with different assays. Here we present a retrospective pharmacometrics (PMX) based data analysis of the rare disease congenital hypothyroidism (CH) in newborns and infants. Our overall aim is to develop a model that can be applied to optimize dosing in this pediatric patient population since suboptimal treatment of CH during the first 2 years of life is associated with a reduced intelligence quotient between 10 and 14 years. The first goal is to describe a retrospectively collected dataset consisting of 61 newborns and infants with CH up to 2 years of age. Overall, 505 measurements of free thyroxine (FT4) and 510 measurements of thyrotropin or thyroid-stimulating hormone were available from patients receiving substitution treatment with levothyroxine (LT4). The second goal is to introduce a scale/location-scale normalization method to merge available FT4 measurements since 34 different postnatal age- and assay-specific laboratory reference ranges were applied. This method takes into account the change of the distribution of FT4 values over time, i.e. a transformation from right-skewed towards normality during LT4 treatment. The third goal is to develop a practical and useful PMX model for LT4 treatment to characterize FT4 measurements, which is applicable within a clinical setting. In summary, a time-dependent normalization method and a practical PMX model are presented. Since there is no on-going or planned development of new pharmacological approaches for CH, PMX based modeling and simulation can be leveraged to personalize dosing with the goal to enhance longer-term neurological outcome in children with the rare disease CH

Modeling of levothyroxine in newborns and infants with congenital hypothyroidism : challenges and opportunities of a rare disease multi-center study

Modeling of retrospectively collected multi-center data of a rare disease in pediatrics is challenging because laboratory data can stem from several decades measured with different assays. Here we present a retrospective pharmacometrics (PMX) based data analysis of the rare disease congenital hypothyroidism (CH) in newborns and infants. Our overall aim is to develop a model that can be applied to optimize dosing in this pediatric patient population since suboptimal treatment of CH during the first 2 years of life is associated with a reduced intelligence quotient between 10 and 14 years. The first goal is to describe a retrospectively collected dataset consisting of 61 newborns and infants with CH up to 2 years of age. Overall, 505 measurements of free thyroxine (FT4) and 510 measurements of thyrotropin or thyroid-stimulating hormone were available from patients receiving substitution treatment with levothyroxine (LT4). The second goal is to introduce a scale/location-scale normalization method to merge available FT4 measurements since 34 different postnatal age- and assay-specific laboratory reference ranges were applied. This method takes into account the change of the distribution of FT4 values over time, i.e. a transformation from right-skewed towards normality during LT4 treatment. The third goal is to develop a practical and useful PMX model for LT4 treatment to characterize FT4 measurements, which is applicable within a clinical setting. In summary, a time-dependent normalization method and a practical PMX model are presented. Since there is no on-going or planned development of new pharmacological approaches for CH, PMX based modeling and simulation can be leveraged to personalize dosing with the goal to enhance longer-term neurological outcome in children with the rare disease CH.publishe